Portfolio Companies News
May 24, 2017Nordic Nanovector ASA – Results f...
Continued progress in clinical development programmes with Betalutin® Oslo, Norway, 24 May 2017 Nordic Nanovector ASA (OSE: NANO) announces results for the first quarter of 2017. A presentation by the company’s senior management team will take place today at 8:30 a.m. CET in Oslo - deta... read more
May 23, 2017Onxeo Announces 10th Positive DSMB ...
Paris (France), May 23, 2017 - 6.00 pm CEST - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the company has... read more
May 23, 2017Aprea Therapeutics Announces First ...
BOSTON and STOCKHOLM, May 23, 2017 /PRNewswire/ Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, announced today that the first patient was enrolled in the Phase Ib/II clinical study of AP... read more
May 23, 2017New Data from Two Multi-Center Rand...
WASHINGTON & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Pulmonx®, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung function after treatment with the Zephyr® Endobronchial Valve (EBV) in emphysema patients without c... read more
May 22, 2017Wilson Therapeutics Strengthens its...
The Annual General Meeting of Wilson Therapeutics AB (publ), has elected Dr. Birgitte Volck and Dr. Björn Odlander as new members of the Board of Directors. Dr. Birgitte Volck is Senior Vice President, Head of R&D Rare Disease at GlaxoSmithKline headquarters in London, UK. Dr. Volck has exte... read more
May 02, 2017Q1 2017 General Market Overview
- 106 Since the start in 1996, HealthCap funds have invested in 106 portfolio companies.
- 40 40 of the portfolio companies have been taken public on nine different markets.
- 22 22 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 6 companies with a valuation of USD 1 billion or more and 34 companies with a valuation of SEK 1 billion or more.